Emerging Approaches to PBC and PSC
|
|
- Nelson Chandler
- 7 years ago
- Views:
Transcription
1 Emerging Approaches to PBC and PSC Keith D. Lindor, MD, FACG Dean, College of Health Solutions Arizona State University OUTLINE PBC Epidemiology Diagnosis Treatment PSC Natural History Treatment Cancer Copyright 2015 American College of Gastroenterology 1
2 PBC Prevalence Boonstra K, Kunst A, Stadhouders P, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-base study. Liver International. 2014;34:e35. PBC Incidence Boonstra K, Kunst A, Stadhouders P, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-base study. Liver International. 2014;34:e35. Copyright 2015 American College of Gastroenterology 2
3 Predictors of Prognosis Yang W, Yu JH, Nakajima,et al. Clin Gastroenterol Hepatol 2004;2(12): Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. J Hepatol 2005;42(3): Higher APRI is Associated with Poorer Transplant-Free/Overall Survival in PBC Trivedi PJ, Bruns T, Cheung A, et al. Optimizing risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol. 2014;60(6): Copyright 2015 American College of Gastroenterology 3
4 Survival Rates, Elastography & PBC Corpechot C, Carrat F, Poujol-Robert A, et al. Hepatology. 2012; 56 (1): Copyright 2015 American College of Gastroenterology 4
5 Role of Liver Biopsy in PBC If: AMA Alk Phos >1.5 times nl AST <5 times normal Then: Positive predictive value for PBC >98% (sensitivity 80%, specificity 92%) Zein CO, Angulo P, Lindor K. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastro and Hepatol 2003;1(2):89-95 Predictors of Esophageal Varices in PBC Levy C, Zein CO, Gomez J, et al. Prevelence and Predictors of Esophageal Varices in Patients with Primary Biliary Cirrhosis. Clin Gastro Hepatol 2007;5(7): Copyright 2015 American College of Gastroenterology 5
6 Medical Approaches to PBC UDCA Survival Free of Transplantation Combined Data Probability of survival % UDCA Placebo & UDCA Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined Analysis of Randomized Controlled Trials of Ursodeoxycholic Acid in Primary Biliary Cirrhosis. Gastroenterology. 1997; 113: Survival in PBC Treated vs. Untreated Treated vs. Population Poupon RE, Bonnand AM, Chretien Y, et al. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology1999; 29(6): Copyright 2015 American College of Gastroenterology 6
7 Natural History of PBC Effects of UDCA Poupon RE, Bonnand AM, Chretien Y, et al. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology. 1999; 29(6): Combination Therapy for PBC Ursodiol Alone Biochemical normalization in ~1/3 Risk scores or alkaline phosphatase response predictive* Various drugs tried in combination Angulo P, Lindor KD, Therneau TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999; 19(2): Copyright 2015 American College of Gastroenterology 7
8 Biochemical Endpoints for Predicting Outcomes Percentage of patients reaching endpoints ALP <1.5 <1.67 <2 >2 >3 Newer Therapies for PBC Bezafibrate/Fenofibrate Silymarin B cell antibodies FXR agonists Copyright 2015 American College of Gastroenterology 8
9 OCA Treatment in Patients with PBC Decreases in ALP Values during DB Phase Change in ALP Values in Completer Population Decreases in ALP Values during Open-Label Extension Change in ALP Values during Open-Label Extension Hirschfield GM, Mason A, Luketic V et al. Efficacy of Obeticholic Acid in Patients with primary biliary cirrhosis and inadequate response to ursodexycholic. Gastroenterology. 2015;148:4. Pruritus Severity in PBC Patients with OCA Pruritus Severity in the Double-Blind Phase Pruritus Severity in the Open- Label OCA Therapy Extension Hirschfield GM, Mason A, Luketic V et al. Efficacy of Obeticholic Acid in Patients with primary biliary cirrhosis and inadequate response to ursodexycholic. Gastroenterology. 2015;148:4. Copyright 2015 American College of Gastroenterology 9
10 Conclusion Regarding Drug Therapy When UDCA is not adequate: Doubling dose is not helpful No clear, proven choices Many promising adjuncts being investigated Hepatocellular Cancer Risk in PBC 18 Patients over 25 years Multivariate Analysis O.R P_ Age 1.6 <.02 Male 5.6 <.05 Hx Transfusion 4.7 <.07 Mayo Risk 1.3 <.02 Copyright 2015 American College of Gastroenterology 10
11 Hepatocellular Carcinoma in PBC Survival probability P=0.002 (log-rank) Time (months) Silveira MG, Suzuki A, Lindor KD. Surveillance for Hepatocellular Carcinoma in Patients with Primary Biliary Cirrhosis. Hepatology 2008;48(4): Conclusions About PBC Becoming more common Slowly progressive, even if asymptomatic Prognostic markers helpful UDCA improves natural history Cancer risk is present Copyright 2015 American College of Gastroenterology 11
12 Histologic Features of PSC Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management. Gastroenterology. 2013; 145: Copyright 2015 American College of Gastroenterology 12
13 Liver Transplantation for PBC & PSC Lee J, Belanger A, Doucette JT, et al. Transplantation Trends in Primary Biliary Cirrhosis. Clin Gastroenterol Hepatol 2007;5(11): PSC Survival in Olmsted County Minnesota Bambha K, Kim WR, Talwalkar, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastro 2003;125(5): Copyright 2015 American College of Gastroenterology 13
14 Ursodiol in PSC High-dose Urso for PSC Results Primary Endpoints UDCA Placebo Death 5 3 Liver Transplant 11 5 Minimal Listing Criteria for Liver Transplant Development of Cirrhosis 6 4 Esophageal and/or Gastric Varices 15 5 Cholangiocarcinoma 2 2 Total Endpoints Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50(3): Copyright 2015 American College of Gastroenterology 14
15 Results Model Of All Primary Endpoints Adjusted For Mayo Risk Score, Presence of Varices, and Stage Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for treatment of primary sclerosing cholangitis. Hepatology 2009;50(3): Kaplan-Meier Analysis of Endpoint Free Survival in all PSC Patients with UDCA Treatment Lindstrom L, Hultcrantz R, Boberg KM,, et al. Assoc. btwen reduced levels of ALK and Survival Times of Patients with PSC. Clin Gastro Hep. 2013;11(7): Copyright 2015 American College of Gastroenterology 15
16 Immunosuppressive and Other Agents Azathioprine Budesonide Docosahexaenoic acid Methotrexate Metronidazole Minocycline Mycophenolate mofetil Nicotine Pentoxifylline Pirfenodone Prednisolone Tacrolimus Vancomycin Vancomycin & Metronidazole in PSC VANCOMYCIN High dose Low dose METRONIDAZOLE Low dose High dose Tabibian JH, Weeding E, Jorgensen RA, et al. Randomized clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis a pilot study. Aliment Pharmacol Ther. 2013; 37(6): Copyright 2015 American College of Gastroenterology 16
17 Autoimmune Pancreatitis/Cholangitis in PSC IgG4 elevated in 9% PSC patients These patients have more aggressive disease These patients may be more steroid responsive. Natural History PSC & IgG4 Proportion without OLT Time (yrs) Mendes F, Jorgensen R, Keach J, et al. Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis. Am J Gastroenterol 2006;101: Copyright 2015 American College of Gastroenterology 17
18 Association of IgG4 and Colectomy Navaneethan U, Venkatesh PGK, Choudhary M, et al. Elevated immunoglobulin G4 level is associated with reduced colectromy-free survival in patients with primary sclerosing cholangitis and ulcerative colitis. Journal of Crohn s and Colitis. 2013; 7: e35 e41. Incidence of Cholangiocarcinoma Cumulative incidence of Cholangiocarcinoma (%) Years since PSC diagnosis Copyright 2015 American College of Gastroenterology 18
19 Elevated CA 19-9 Values in PSC *T bars represent interquartile range of the values Sinakos E, Saenger AK, Keach J, et al. Many Patients with Primary Sclerosing Cholangitis and Increased Serum Levels of Carbohydrate Antigen 19-9 Do Not Have Cholangiocarinoma. Clin Gastroenterol Hepatol 2011;9(5): Colon Cancer/IBD/PSC 50% PSC/CUC CUC Risk % 31% 9% 2% 5% 10% 10 Years 20 Years 25 Years Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology. 1995;22(5): Copyright 2015 American College of Gastroenterology 19
20 High-Dose Urso in UC & PSC Patients Eaton J, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106(9): UDCA and Risk of Colorectal Neoplasia in Patients with PSC - IBD Singh S, Khanna S, Pardi DS,, et al. Effect of UDCA on the Risk of Colorectal Neoplasia in Patients with PSC and IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2013;19(8): Copyright 2015 American College of Gastroenterology 20
21 UDCA and Risk of Advanced Colorectal Neoplasia in Patients with PSC - IBD Singh S, Khanna S, Pardi DS,, et al. Effect of UDCA on the Risk of Colorectal Neoplasia in Patients with PSC and IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2013;19(8): Take Home Points PBC Ursodiol is treatment Obeticholic acid promising Liver cancer risk present PSC No established therapy Ursodiol role being defined High does UDCA (28 30 mg/kg/day) to be avoided Risk of bile duct and colon cancer Copyright 2015 American College of Gastroenterology 21
NASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center
NASH: It is not JUST a Fatty Liver Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center Stages of Fatty Liver Disorders Fatty Liver 16-35% of Western
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationBACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
More informationIBD: Ulcerative Colitis Monday, February 10, 2014 The Fairmont Royal York Toronto, ON
IBD: Ulcerative Colitis Monday, February 10, 2014 The Fairmont Royal York Toronto, ON Accreditation This event has been approved as an accredited (Section1) group learning activity as defined by the Maintenance
More informationSubproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases
Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases M. Trauner, Division of Gastroenterology and Hepatology, Department of Internal Medicine, MUG Co- Investigator: H. Samonigg,
More informationApproach to Abnormal Liver Tests
Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationAASLD PRACTICE GUIDELINES Diagnosis and Management of Primary Sclerosing Cholangitis
AASLD PRACTICE GUIDELINES Diagnosis and Management of Primary Sclerosing Cholangitis Roger Chapman, 1 Johan Fevery, 2 Anthony Kalloo, 3 David M. Nagorney, 4 Kirsten Muri Boberg, 5 Benjamin Shneider, 6
More informationBile Duct Diseases and Problems
Bile Duct Diseases and Problems Introduction A bile duct is a tube that carries bile between the liver and gallbladder and the intestine. Bile is a substance made by the liver that helps with digestion.
More informationAUTOIMMUNE HEPATOBILIARY DISEASE: HOW TO IMPROVE TREATMENT EFFICACY
AUTOIMMUNE HEPATOBILIARY DISEASE: HOW TO IMPROVE TREATMENT EFFICACY AISF Pre-Meeting 2015 Rome, 18 Feb Ana Lleo, MD PhD Liver Unit and Center for Autoimmune Liver Diseases Humanitas Clinical and Research
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More informationAbnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London
Abnormal Liver Function Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related
More informationUlcerative colitis patients with low grade dysplasia should undergo frequent surveillance colonoscopies
Ulcerative colitis patients with low grade dysplasia should undergo frequent surveillance colonoscopies David T. Rubin, MD, FACG, AGAF Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease
More informationFast Facts. Fast Facts: Liver Disorders. Thomas Mahl and John O Grady. 2006 Health Press Ltd. www.fastfacts.com
Fast Facts Fast Facts: Liver Disorders Thomas Mahl and John O Grady 2006 Health Press Ltd. www.fastfacts.com Fast Facts Fast Facts: Liver Disorders Thomas Mahl MD University at Buffalo School of Medicine
More informationTREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER
Press information for journalists only TREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER Why treat IBD? IBD describes a range of chronic diseases of the gastrointestinal system, encompassing Ulcerative
More informationLiver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationResearch in IBD at University of Colorado Denver
Research in IBD at University of Colorado Denver Blair Fennimore, MD Assistant Professor of Medicine Division of Gastroenterology and Hepatology UCH Crohn s and Colitis Center Mucosal Inflammation Program
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Multiple Technology Appraisal Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional
More informationWhat to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
More informationRecommendations 8/14/2014. Hepatitis C Clinical Approach Primary Care. Purpose of Presentation. HCV Prevalence Year of Birth
Hepatitis C Clinical Approach Primary Care Dr. Vicki L. MIt McIntyre, FNP Tucson Gastroenterology Specialists Tucson, Arizona University of Phoenix Lead Faculty, Department of Nursing Tucson, Arizona Purpose
More informationEvaluation of Liver Function tests in Primary Care. Abid Suddle Institute of Liver Studies, KCH
Evaluation of Liver Function tests in Primary Care Abid Suddle Institute of Liver Studies, KCH Liver Function tests Markers of hepatocellular damage Cholestasis Liver synthetic function Markers of Hepatocellular
More informationEVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze
EVIDENCE BASED TREATMENT OF CROHN S DISEASE Dr E Ndabaneze PLAN 1. Case presentation 2. Topic on Evidence based Treatment of Crohn s disease - Introduction pathology aetiology - Treatment - concept of
More informationMeasures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationBSc in Medical Sciences with GASTROENTEROLOGY AND HEPATOLOGY
BSc in Medical Sciences with GASTROENTEROLOGY AND HEPATOLOGY Introduction The BSc in Gastroenterology and Hepatology allows a science-based study of the physiology, cell biology, pathology and pharmacology
More informationEvaluation of a Child with Elevated Transaminases. Linda V. Muir, M.D. April 11, 2008 Northwest Pediatric Liver Disease Symposium
Evaluation of a Child with Elevated Transaminases Linda V. Muir, M.D. April 11, 2008 Northwest Pediatric Liver Disease Symposium Disclosures I do not have a financial interest, arrangement or affiliation
More informationAutoimmune pancreatitis. Lars Aabakken Oslo University Hospital - Rikshospitalet Oslo, Norway
Autoimmune pancreatitis Lars Aabakken Oslo University Hospital - Rikshospitalet Oslo, Norway Autoimmune pancreatitis Concept introduced in 1961 (Sarles) Re-invented in Japan 1995 (Yoshida) Increasingly
More informationPrimary biliary cirrhosis (PBC) is a progressive cholestatic
Increased Prevalence of Antimitochondrial Antibodies in First-Degree Relatives of Patients with Primary Biliary Cirrhosis Konstantinos N. Lazaridis, 1 Brian D. Juran, 1 Gwen M. Boe, 1 Joshua P. Slusser,
More informationAlcoholic Hepatitis (Teacher s Guide)
Thomas Ormiston, M.D. Updated 5/5/15 2007-2015, SCVMC Alcoholic Hepatitis (Teacher s Guide) (30 minutes) I. Objectives Recognize the signs and symptoms of alcoholic hepatitis Understand the treatment options
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationEvaluation of abnormal LFT in the asymptomatic patient. Son Do, M.D. Advanced Gastroenterology Vancouver, WA
Evaluation of abnormal LFT in the asymptomatic patient Son Do, M.D. Advanced Gastroenterology Vancouver, WA Definition of chronic, abnormally elevated LFT Elevation of one or more of the following for
More informationDr Alessandro Armuzzi, UOC di Medicina Interna e Gastroenterologia Complesso Integrato Columbus Università Cattolica
Dr Alessandro Armuzzi, UOC di Medicina Interna e Gastroenterologia Complesso Integrato Columbus Università Cattolica Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse
More informationHow does the disease activity of Ulcerative Colitis relate to the incidence of Colon cancer? A) Study Purpose and Rationale
How does the disease activity of Ulcerative Colitis relate to the incidence of Colon cancer? A) Study Purpose and Rationale Ulcerative colitis is a disease of the colon that affects 1:1000 individuals,
More informationAutoimmune Hepatitis/ Autoimmune Pancreatitis. Edmund Krasinski, Jr., D.O. F.A.C.G.
Autoimmune Hepatitis/ Autoimmune Pancreatitis Edmund Krasinski, Jr., D.O. F.A.C.G. Assessment of Liver Function Which of the following is not a good biochemical assessor of hepatic function? A) Serum bilirubin
More informationClostridium Difficile Colitis. Presented by Mark Skains August 2003
Clostridium Difficile Colitis Presented by Mark Skains August 2003 What is Clostridium Difficile Gram positive rod Produces spores (hang out in diverticula) Forms Endotoxin A + B which cause diarrhea.
More informationTop Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms. Stephen B. Hanauer, M.D. University of Chicago
Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms Stephen B. Hanauer, M.D. University of Chicago Treatment Goals c.2008 Induce and maintain response/remission Prevent complications Disease
More informationAASLD PRACTICE GUIDELINES Primary Biliary Cirrhosis
AASLD PRACTICE GUIDELINES Primary Biliary Cirrhosis Keith D. Lindor, 1 M. Eric Gershwin, 2 Raoul Poupon, 3 Marshall Kaplan, 4 Nora V. Bergasa, 5 and E. Jenny Heathcote 6 This guideline has been approved
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More informationHCV: Diagnostic Testing and Staging. HCV: Diagnostic Tests
HCV: Diagnostic Testing and Staging HCV: Diagnostic Tests Necessary HCV Antibody HCV-RNA Genotype Not Necessary ALT IL28 B 1 ALT as a Sole Trigger for Screening Misses Some Infected Patients Patients*
More informationNon-alcoholic fatty liver disease: Prognosis and Treatment
Non-alcoholic fatty liver disease: Prognosis and Treatment Zachary Henry, M.D. Assistant Professor UVA Gastroenterology & Hepatology October 28, 2015 Overview Case Presentation Prognosis Effects of fibrosis
More informationCancer Screening. Robert L. Robinson, MD, MS. Ambulatory Conference SIU School of Medicine Department of Internal Medicine.
Cancer Screening Robert L. Robinson, MD, MS Ambulatory Conference SIU School of Medicine Department of Internal Medicine March 13, 2003 Why screen for cancer? Early diagnosis often has a favorable prognosis
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationAutoimmune Hepatitis. AIH: Clinical Features. Autoimmune Hepatitis (AIH) Core Curriculum In Hepatology And Liver Transplantation 2012-13
Core Curriculum In Hepatology And Liver Transplantation 2012-13 Autoimmune Liver Diseases: AIH, PBC, PSC November 20 th, 2012 Professor Suzanne Norris, PhD, FRCPI, Consultant Hepatologist, St. James Hospital,
More informationStudy of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis
Research Article Study of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis RR. Pawar*, ML. Pardeshi and BB. Ghongane Department of Pharmacology, B.J. Medical
More informationLiver Diseases. An Essential Guide for Nurses and Health Care Professionals
Brochure More information from http://www.researchandmarkets.com/reports/1047385/ Liver Diseases. An Essential Guide for Nurses and Health Care Professionals Description: Liver disease is a rapidly growing
More informationLong-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
More informationThe child with abnormal liver function tests
The child with abnormal liver function tests Dr Jane Hartley Consultant Paediatric Hepatologist Birmingham Children s Hospital, UK 1 st Global Congress CIP, Paris 2011 Contents Over view of liver anatomy,
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More information11/10/2014. New Treatments in IBD: When, Whom and How. Background. Background. Options. Disease Assessment. What is the evidence?
New Treatments in IBD: When, Whom and How. Background Options Disease Assessment What is the evidence? Kofi Clarke MD, FACP,FRCP (Lond) Clinical Associate Professor, Chief, Gastroenterology, Hepatology
More informationManaging LFT s in General Practice
Managing LFT s in General Practice Sulleman Moreea FRCP(Edin Edin) ) FRCS(Glasg Glasg) Consultant Gastroenterologist/Hepatologist Bradford Hospitals Trust The normal liver Managing LFT s History and examination
More informationClinical guideline Published: 23 March 2011 nice.org.uk/guidance/cg118. NICE 2011. All rights reserved.
Colorectal cancer prevention: ention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Clinical guideline Published: 23 March 2011 nice.org.uk/guidance/cg118 NICE
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationEvidence of Crohn s Disease. Case Presentation
Witt Wait to Treat tutiled Until Endoscopic Evidence of Crohn s Disease Raymond Cross, MD, MS, AGAF Associate Professor of Medicine Director, IBD Program University of Maryland School of Medicine Co-Director,
More informationThe economic cost and health burden of liver diseases in Australia. The Gastroenterological Society of Australia/Australian Liver Association
The economic cost and health burden of liver diseases in Australia The Gastroenterological Society of Australia/Australian Liver Association January 2013 Contents Glossary of acronyms... i Executive summary...
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationMR imaging of primary sclerosing cholangitis (PSC) using the hepatobiliary specific contrast agent Gd-EOB-DTPA
MR imaging of primary sclerosing cholangitis (PSC) using the hepatobiliary specific contrast agent Gd-EOB-DTPA Poster No.: C-0019 Congress: ECR 2010 Type: Educational Exhibit Topic: Abdominal Viscera (Solid
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationNew and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents
New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine
More informationInterpretation of liver chemistry tests
Interpretation of liver chemistry tests Fuad A.M. Hasan, Salim Owyed Bulletin of KIMS carries some articles specifically designated as CME/CPD. They provide the opportunity for the reader to obtain credit
More informationStephen R. Veach, M.D.
Stephen R. Veach, M.D. Memorial Sloan-Kettering Cancer Center International Oncology Programs 160 E. 53 rd Street New York, NY 10022 212-610 610-08780878 - tel 212-308 308-7063 - fax veachs@mskcc.org SCREENING
More informationWhat is the Real Function of the Liver Function Tests?
Ulster Med J 2012;81(1):30-36 Grand Rounds What is the Real Function of the Liver Function Tests? Philip Hall, Johnny Cash Accepted 24 August 2011 Abstract Liver enzymes are commonly used in the evaluation
More informationPSC and Your Liver: How to Keep Your Liver Healthy: Myths and Reality
PSC and Your Liver: How to Keep Your Liver Healthy: Myths and Reality Kapil Chopra, MD Associate Professor of Medicine Clinical Director of Hepatology PSC Liver: Pubmed Publications 100 90 80 70 60 50
More informationTHE NEW INTERCEPT STRATEGY FOR OCA AND THE IMPACT OF GENFIT- GFT505 MARKET
THE NEW INTERCEPT STRATEGY FOR OCA AND THE IMPACT OF GENFIT- GFT505 MARKET (G DIVRY- March the 22th, 2015) The new strategy of Intercept for OCA seems to be revealed in their communication last Friday
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationUpdate on hepatitis C: treatment and care and future directions
Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationRecommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center
More informationDrugs Believed Capable of Inducing Autoimmune Hepatitis
Drugs Believed Capable of Inducing Autoimmune Hepatitis Leonard B. Seeff, M.D. National Institutes of Diabetes and Digestive and Kidney Diseases National Institutes of Health Immune-Mediated Liver Diseases
More informationEvaluation and Prognosis of Patients with Cirrhosis
Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded
More informationEASL Clinical Practice Guidelines: Management of cholestatic liver diseases
Journal of Hepatology 51 (2009) 237 267 www.elsevier.com/locate/jhep EASL Clinical Practice Guidelines: Management of cholestatic liver diseases European Association for the Study of the Liver * Keywords:
More informationManagement of Primary Biliary Cirrhosis
AASLD Practice Guidelines Management of Primary Biliary Cirrhosis E. JENNY HEATHCOTE Primary biliary cirrhosis (PBC) is a presumed autoimmune disease of the liver, which predominantly affects women once
More informationAntibiotic-Associated Diarrhea, Clostridium difficile- Associated Diarrhea and Colitis
Antibiotic-Associated Diarrhea, Clostridium difficile- Associated Diarrhea and Colitis ANTIBIOTIC-ASSOCIATED DIARRHEA Disturbance of the normal colonic microflora Leading to alterations in bacterial degradation
More informationLiver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to
Manifesto by the European Liver Patients Association (ELPA) on policy measures against chronic liver disease 2014 to 2019 Why this manifesto? Every five years European voters get the opportunity to have
More informationCase Study in the Management of Patients with Hepatocellular Carcinoma
Management of Patients with Viral Hepatitis, Paris, 2004 Case Study in the Management of Patients with Hepatocellular Carcinoma Eugene R. Schiff This 50-year-old married man with three children has a history
More informationHEPATOLOGY CLERKSHIP
College of Osteopathic Medicine HEPATOLOGY CLERKSHIP Office for Clinical Affairs 515-271-1629 FAX 515-271-1727 Elective Rotation General Description This elective rotation is a four (4) week introductory,
More informationTerapia con farmaci biologici e non nella. Sandro Ardizzone. Azienda Ospedaliera Fatebenefratelli e. Ospedale di Rilievo Nazionale Milan
Terapia con farmaci biologici e non nella Colite Ulcerosa Severa/Refrattaria Sandro Ardizzone Gastrointestinal Unit Azienda Ospedaliera Fatebenefratelli e Oftalmico Ospedale di Rilievo Nazionale Milan
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationLiver Disease Research Updates. Liver Disease Research. What is Research?
Liver Disease Research Liver Disease Research Updates Nikunj Shah, MD Medical Director of Liver Transplantation Associate Professor of Medicine University of Illinois Medical Center What is research? Types
More informationComparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases
Available online at wwwpelagiaresearchlibrarycom European Journal of Experimental Biology, 2013, 3(2):280-284 ISSN: 2248 9215 CODEN (USA): EJEBAU Comparative Levels of ALT, AST, ALP and GGT in Liver associated
More informationLiver Function Tests - The Downside
KAPIL CHOPRA, MD 1 So I'm going to kickoff this course with the topic of abnormal liver function tests. To be very honest this is a huge topic. I think to do justice I'm going to try and touch on some
More informationJuly 30, 2012. Probable Link Evaluation of Autoimmune Disease
1 July 30, 2012 Probable Link Evaluation of Autoimmune Disease Conclusion: On the basis of epidemiological and other data available to the C8 Science Panel, we conclude that there is a probable link between
More informationHow To Treat Liver Cancer With Udca
Methotrexate () Plus Ursodeoxycholic Acid (UDCA) in the Treatment of Primary Biliary Cirrhosis Burton Combes, 1 Scott S. Emerson, 2 Nancy L. Flye, 2 Santiago J. Munoz, 3 Velimir A. Luketic, 4 Marlyn J.
More informationInflammatory Bowel Disease. (Ulcerative Colitis and Crohn s Disease)
Ministry of Defence Synopsis of Causation Inflammatory Bowel Disease (Ulcerative Colitis and Crohn s Disease) Authors: Dr Hazel Younger, Ninewells Hospital and Medical School, Dundee and Dr Craig Mowat,
More informationChronic Hepatitis/Chronic Active Hepatitis in Dogs
Chronic Hepatitis/Chronic Active Hepatitis in Dogs Robert M. Hardy, DVM, MS, Diplomate ACVIM (Internal Medicine) Department of Small Animal Clinical Sciences College of Veterinary Medicine University of
More informationThe State of the Liver in the Adult Patient after Fontan Palliation
The State of the Liver in the Adult Patient after Fontan Palliation Fred Wu, M.D. Boston Adult Congenital Heart Service Boston Children s Hospital/Brigham & Women s Hospital 7 th National Adult Congenital
More informationUCLA Asian Liver Program
CLA Program Update Program Faculty Myron J. Tong, PhD, MD Professor of Medicine Hepatology Director, Asian Liver Program Surgery Ronald W. Busuttil, MD, PhD Executive Chair Department of Surgery Director,
More informationColonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn s disease or adenomas
1 2 3 4 Colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn s disease or adenomas 5 6 7 Full guideline Draft, September 2010 8 9 This guideline was
More information11/8/2011. Administrative Definitions of Rheumatoid Arthritis: Rising Prevalence Regardless of Definition Used. No Disclosures. Background.
Administrative Definitions of Rheumatoid Arthritis: Rising Prevalence Regardless of Definition Used Christine A. Peschken, Carol A. Hitchon, Hui Chen, Allan Garland, Hani S. El-Gabalawy, Charles N. Bernstein
More informationLAB 1 - Direct agglutination. Serology-the study of the in vitro reactions between antibody and antigen
LAB 1 - Direct agglutination Serology-the study of the in vitro reactions between antibody and antigen Serological reaction: - quantitative (weight/volume) - qualitative Agglutination - the aggregation
More informationCarbohydrate antigen 19 9 (CA 19 9) (serum, plasma)
Carbohydrate antigen 19 9 (CA 19 9) (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Carbohydrate antigen 19 9 (CA 19 9) 1.2 Alternative names Cancer antigen 19 9, cancer antigen GI
More informationHCV: Diagnostic Testing and Staging. HCV: Diagnostic Tests
HCV: Diagnostic Testing and Staging HCV: Diagnostic Tests Necessary HCV Antibody HCV-RNA Genotype Not Necessary ALT IL28 B 1 ALT as a Sole Trigger for Screening Misses Some Infected Patients Patients*
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationDisorders of the hepatobiliary system are relatively common
INVITED REVIEW The Liver in Pediatric Gastrointestinal Disease Hanh D. Vo, Jiliu Xu, Simon S. Rabinowitz, Stanley E. Fisher, and Steven M. Schwarz ABSTRACT Hepatic involvement is often encountered in gastrointestinal
More informationNoninvasive Means of Diagnosing Liver Fibrosis in Hepatitis C*
530 BJID 2007; 11 (December) Noninvasive Means of Diagnosing Liver Fibrosis in Hepatitis C* Eduardo Sellan Lopes Gonçales, Adriana Flávia Feltrim Angerami and Fernando Lopes Gonçales Junior Study Group
More informationEpidemiology and treatment of gallstones in 2010
Epidemiology and treatment of gallstones in 2010 Adolfo Francesco Attili Università di Roma La Sapienza Rome, october 8, 2008 Fasi degli studi epidemiologici 1. Trasversale (prevalenza e fattori associati)
More informationNon Alcoholic Steato-Hepatitis (NASH)
Non Alcoholic Steato-Hepatitis (NASH) DISCLAIMER NEITHER THE PUBLISHER NOR THE AUTHORS ASSUME ANY LIABILITY FOR ANY INJURY AND OR DAMAGE TO PERSONS OR PROPERTY ARISING FROM THIS WEBSITE AND ITS CONTENT.
More informationWhat are the Unmet Needs in the Management of IBD?
23/6/214 What are the Unmet Needs in the Management of IBD? Shane Devlin, MD, FRCPC Inflammatory Bowel Disease Group The University of Calgary Some Real Cases: #1 32 yo male with pan UC. Grumbling phenotype
More informationBritish Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis
British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis Dermot Gleeson, 1 Michael A Heneghan 2 Guidelines 1 Liver Unit, Sheffield Teaching Hospitals Foundation Trust,
More information